Health-Related Quality of Life for Patients Receiving Tumor Treating Fields for Glioblastoma
BackgroundTo date, there has been no large-scale, real-world study of the health-related quality of life outcomes for patients using tumor treating fields (TTFields) therapy for glioblastoma (GBM) treatment.MethodsA survey was mailed to 2,815 patients actively using TTFields for treatment of GBM in...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.772261/full |
| _version_ | 1818839820181438464 |
|---|---|
| author | Joshua D. Palmer Gordon Chavez Wesley Furnback Po-Ya Chuang Bruce Wang Christina Proescholdt Chao-Hsiun Tang |
| author_facet | Joshua D. Palmer Gordon Chavez Wesley Furnback Po-Ya Chuang Bruce Wang Christina Proescholdt Chao-Hsiun Tang |
| author_sort | Joshua D. Palmer |
| collection | DOAJ |
| description | BackgroundTo date, there has been no large-scale, real-world study of the health-related quality of life outcomes for patients using tumor treating fields (TTFields) therapy for glioblastoma (GBM) treatment.MethodsA survey was mailed to 2,815 patients actively using TTFields for treatment of GBM in the USA (n = 2,182) and Europe (n = 633). The survey included patient-reported demographic and clinical information, as well as EuroQol’s EQ-5D-5L and visual analogue scale (EQ-VAS) overall health score.ResultsA total of 1,106 applicable patients responded to the survey (USA = 782 and Europe = 324), with a mean age of 58.6 years (SD = 12.3). The average time since diagnosis and time using TTFields were 21.5 months (SD = 25.1) and 13.5 months (SD = 13.2), respectively. Over 61% of patients had been diagnosed at least 1 year prior and 28.4% at least 2 years prior; 45 patients (4.2%) had been diagnosed at least 5 years prior. Progressed disease was reported in 307 patients, while 690 reported non-progressed disease. Regression analyses showed that GBM disease progression and older age had predictable negative associations (p < 0.001) with most EQ-5D-5L dimensions and the EQ-VAS. However, longer time since diagnosis was associated with improved self-care (p < 0.05), usual activities (p < 0.01), and EQ-VAS (p < 0.05) overall and in patients with progressed disease (p < 0.01, p < 0.05, and p < 0.01, respectively). Additionally, longer time using TTFields was associated with improved mobility (p < 0.05), self-care (p < 0.001), usual activities (p < 0.01), and EQ-VAS (p < 0.01) overall; with improved EQ-VAS in progression-free patients (p < 0.05); and with improved mobility (p < 0.05), self-care (p < 0.01), usual activities (p < 0.05), and EQ-VAS (p < 0.05) in patients with progressed disease.ConclusionThis is the largest real-world study of patient-reported quality of life in GBM and TTFields treatment to date. It shows unsurprising negative associations between quality of life and disease progression and older age, as well as more novel, positive associations between quality of life and longer time since diagnosis and time using TTFields therapy. |
| first_indexed | 2024-12-19T04:00:22Z |
| format | Article |
| id | doaj.art-c221ce71a4484dd5b76a341b782eca83 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-19T04:00:22Z |
| publishDate | 2021-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-c221ce71a4484dd5b76a341b782eca832022-12-21T20:36:41ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-12-011110.3389/fonc.2021.772261772261Health-Related Quality of Life for Patients Receiving Tumor Treating Fields for GlioblastomaJoshua D. Palmer0Gordon Chavez1Wesley Furnback2Po-Ya Chuang3Bruce Wang4Christina Proescholdt5Chao-Hsiun Tang6The James Cancer Hospital and Solove Research Institute at the Ohio State University, Columbus, OH, United StatesDepartment of Global Value, Novocure, New York, NY, United StatesDepartment of Value and Access, Real Chemistry, New York, NY, United StatesDepartment of Value and Access, Real Chemistry, New York, NY, United StatesDepartment of Value and Access, Real Chemistry, New York, NY, United StatesDepartment of Global Value, Novocure, Root, SwitzerlandSchool of Health Care Administration, Taipei Medical University, Taipei, TaiwanBackgroundTo date, there has been no large-scale, real-world study of the health-related quality of life outcomes for patients using tumor treating fields (TTFields) therapy for glioblastoma (GBM) treatment.MethodsA survey was mailed to 2,815 patients actively using TTFields for treatment of GBM in the USA (n = 2,182) and Europe (n = 633). The survey included patient-reported demographic and clinical information, as well as EuroQol’s EQ-5D-5L and visual analogue scale (EQ-VAS) overall health score.ResultsA total of 1,106 applicable patients responded to the survey (USA = 782 and Europe = 324), with a mean age of 58.6 years (SD = 12.3). The average time since diagnosis and time using TTFields were 21.5 months (SD = 25.1) and 13.5 months (SD = 13.2), respectively. Over 61% of patients had been diagnosed at least 1 year prior and 28.4% at least 2 years prior; 45 patients (4.2%) had been diagnosed at least 5 years prior. Progressed disease was reported in 307 patients, while 690 reported non-progressed disease. Regression analyses showed that GBM disease progression and older age had predictable negative associations (p < 0.001) with most EQ-5D-5L dimensions and the EQ-VAS. However, longer time since diagnosis was associated with improved self-care (p < 0.05), usual activities (p < 0.01), and EQ-VAS (p < 0.05) overall and in patients with progressed disease (p < 0.01, p < 0.05, and p < 0.01, respectively). Additionally, longer time using TTFields was associated with improved mobility (p < 0.05), self-care (p < 0.001), usual activities (p < 0.01), and EQ-VAS (p < 0.01) overall; with improved EQ-VAS in progression-free patients (p < 0.05); and with improved mobility (p < 0.05), self-care (p < 0.01), usual activities (p < 0.05), and EQ-VAS (p < 0.05) in patients with progressed disease.ConclusionThis is the largest real-world study of patient-reported quality of life in GBM and TTFields treatment to date. It shows unsurprising negative associations between quality of life and disease progression and older age, as well as more novel, positive associations between quality of life and longer time since diagnosis and time using TTFields therapy.https://www.frontiersin.org/articles/10.3389/fonc.2021.772261/fullglioblastomatumor treating fieldsquality of lifeEQ-5Dreal-world evidence |
| spellingShingle | Joshua D. Palmer Gordon Chavez Wesley Furnback Po-Ya Chuang Bruce Wang Christina Proescholdt Chao-Hsiun Tang Health-Related Quality of Life for Patients Receiving Tumor Treating Fields for Glioblastoma Frontiers in Oncology glioblastoma tumor treating fields quality of life EQ-5D real-world evidence |
| title | Health-Related Quality of Life for Patients Receiving Tumor Treating Fields for Glioblastoma |
| title_full | Health-Related Quality of Life for Patients Receiving Tumor Treating Fields for Glioblastoma |
| title_fullStr | Health-Related Quality of Life for Patients Receiving Tumor Treating Fields for Glioblastoma |
| title_full_unstemmed | Health-Related Quality of Life for Patients Receiving Tumor Treating Fields for Glioblastoma |
| title_short | Health-Related Quality of Life for Patients Receiving Tumor Treating Fields for Glioblastoma |
| title_sort | health related quality of life for patients receiving tumor treating fields for glioblastoma |
| topic | glioblastoma tumor treating fields quality of life EQ-5D real-world evidence |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.772261/full |
| work_keys_str_mv | AT joshuadpalmer healthrelatedqualityoflifeforpatientsreceivingtumortreatingfieldsforglioblastoma AT gordonchavez healthrelatedqualityoflifeforpatientsreceivingtumortreatingfieldsforglioblastoma AT wesleyfurnback healthrelatedqualityoflifeforpatientsreceivingtumortreatingfieldsforglioblastoma AT poyachuang healthrelatedqualityoflifeforpatientsreceivingtumortreatingfieldsforglioblastoma AT brucewang healthrelatedqualityoflifeforpatientsreceivingtumortreatingfieldsforglioblastoma AT christinaproescholdt healthrelatedqualityoflifeforpatientsreceivingtumortreatingfieldsforglioblastoma AT chaohsiuntang healthrelatedqualityoflifeforpatientsreceivingtumortreatingfieldsforglioblastoma |